Madrigal Pharmaceuticals, Inc. Earnings

Madrigal Pharmaceuticals, Inc.’s revenue jumped 13318.18% since last year same period to $103.32Mn in the Q4 2024. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 66.18% jump in its revenue since last 3-months.

Madrigal Pharmaceuticals, Inc.’s net profit jumped 47.04% since last year same period to $-59.42Mn in the Q4 2024. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 44.45% jump in its net profits since last 3-months.

Madrigal Pharmaceuticals, Inc.’s net profit margin jumped 99.61% since last year same period to -57.51% in the Q4 2024. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 66.57% jump in its net profit margins since last 3-months.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -6.28 - a -52.26% fall from last quarter’s estimates.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -6.28.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) jumped 52.29% since last year same period to -2.71 in the Q4 2024. This indicates that the Madrigal Pharmaceuticals, Inc. has generated 52.29% annual rate of jump in its earning per share (EPS) in the last 4 quarters.